Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jul 14, 2021 5:13pm
236 Views
Post# 33546000

RE:RE:RE::-)

RE:RE:RE::-)
woundedknee wrote: Have to agree with Yukon and I'm sane, for now anyway. The delay in P3 until possibly this time next year, and more importantly, the second major insider sale by our man Dan, are the only two reasons for the sell off. Very reckless and damaging to this comany imo.  The arguement that he sold shares to pay off a 300g tax bill is a poor excuse. Maybe he did have a big tax bill to pay, but as CEO he should have known what damage this would do to the sp and used other means to pay. Out nearly 40 Gs on paper and counting. I stated a while back that this will break 3 bucks, but personally I have no choice but to continue to hold and hope that a successfull P3 trial (whenever that will be) will turn this around. I'm sure the analysts will be updating their price targets soon. Oh well, Mugsy keeps chipping away at these "cheapies". Does Dan have millions of shares Marky? Maybe before the RS, but not now. And to compare him to Joe Biden really says this company is in trouble. Or have you been under a rock for the last 6 months. The man has dementia!
Let's hope this will all work out in the end. But this is going to be a gut wrenching ride for anyone holding on. jmo and gl to all long shareholders.


Yes Sir Wounded.
More than usual today !!!

<< Previous
Bullboard Posts
Next >>